ConcertAI

Cholangiocarcinoma (CCA) has a poor prognosis at an advanced stage, with a median overall survival of about 12–15 months. Futibatinib and pemigatinib are FGFR2 inhibitors approved by the US FDA in 2023 and 2020, respectively, to treat CCA. We performed a retrospective study using the ConcertAI RWD360® dataset, including CCA patients who initiated futibatinib (N=122) or pemigatinib (N=93) in 2023 or later. From the start of these index treatments, futibatinib patients had numerically longer median real-world overall survival (rwOS) than pemigatinib patients (10.5 vs. 9.6 months), though the difference was not statistically significant (p=0.39). Time to next treatment or death and time to treatment discontinuation were also similar in the two groups, as was frequency of occurrence of medical events of interest. These findings suggest that futibatinib is a promising alternative in this patient population. Learn more during the poster presentation at #ASCO26 Hall A | Abstract 4109 | Poster 92 Saturday, May 30 | 9:00–12:00 PM Read abstract: https://lnkd.in/gyRHd2wr #Oncology #Cholangiocarcinoma #RealWorldData #CancerResearch #ConcertAI

AI in clinical trials is moving beyond potential to measurable impact. From improving patient identification and trial matching to accelerating study timelines and reducing operational burden, AI is helping reshape how clinical research is conducted across the healthcare ecosystem. In our latest blog, we explore how AI-driven approaches are delivering real-world value today — and what’s needed to scale innovation responsibly across clinical development. Read more: https://lnkd.in/gQs_C-mu #ConcertAI #ClinicalTrials #AI #HealthcareInnovation #LifeSciences #RealWorldData #ASCO26

Today on #NationalClinicalTrialsDay, we recognize the patients, clinicians, researchers, sponsors, and trial teams advancing the future of medicine through clinical research. As clinical development grows more complex, the opportunity to improve speed, connectivity, and access has never been greater. Through AI-powered insights and high-integrity real-world data, ConcertAI is proud to support the clinical research community in helping accelerate evidence generation and trial execution. Progress in healthcare depends on collaboration, innovation, and a shared commitment to bringing new therapies to patients faster. Thank you to everyone helping move research forward. #ClinicalTrialsDay #ClinicalResearch #LifeSciences #AIinHealthcare #RealWorldEvidence

As cancer care becomes increasingly complex, access to timely, actionable data is more important than ever. ConcertAI’s CancerLinQ® continues to help oncology organizations leverage real-world insights to support quality improvement, personalized care, and research innovation across cancer care. We’re proud to welcome Wilmot Cancer Institute and University of Colorado Anschutz Cancer Center to the growing CancerLinQ network as we continue advancing data-driven oncology care together. Read announcement: https://hubs.ly/Q04hhQ0k0 #ConcertAI #CancerLinQ #Oncology #AIinHealthcare #RealWorldData #PrecisionMedicine

Cancer care and oncology research are evolving rapidly — and the need for smarter, more actionable intelligence has never been greater. At #ASCO26, ConcertAI will showcase how we combine clinical expertise, real-world data, and applied AI to help advance oncology research, clinical development, and evidence generation. We’re looking forward to connecting in Chicago, May 29–June 2. Book time with our team: https://hubs.ly/Q04gwKsv0 #Oncology #AI #RealWorldData #PrecisionMedicine #ClinicalResearch #LifeSciences #ConcertAI

We’re excited to share a new ConcertAI publication being presented at #ISPOR2026 on Monday, May 18 from 10:30 AM – 1:30 PM. Don't miss Poster #3036 - Comparing LLM-based to Expert-Curated Extraction for Biomarker Attributes in Lung and Breast Cancer! Extracting a single biomarker name from a clinical note is the easy part. The harder problem is capturing the full attribute set — categorical result, variant type, genomic alteration, exon number — from the same unstructured EHR text, across multiple biomarkers, reliably at scale. We built and validated a multi-agent LLM/SLM pipeline trained on real-world oncology EHR data to do exactly that, benchmarked against expert-curated annotations across 11 biomarkers in lung and breast cancer. Biomarker identification reached F1 scores up to 1.00, with categorical result F1 ≥ 0.82 across the majority of biomarkers — and the model held up against some genuinely hard clinical language challenges: negation scope, assertion state, and implicit positivity notation. There's more work ahead on complex attributes, but the foundation is strong. Congratulations to the full team: Sheenu Chandwani, Payal Keswarpu, Ashwani Yadav, Vivek Vaidya, Jiby Joseph MD, MS, and Ruth Pe Benito. Read more: https://hubs.ly/Q04gMP8F0 #ISPOR2026 #Oncology #LLM #ArtificialIntelligence #RealWorldData #PrecisionMedicine #ConcertAI

What if clinical trial timelines could be accelerated without sacrificing quality or confidence in the results? Our latest ConcertAI white paper explores how AI and real-world data are helping life sciences organizations streamline study design, feasibility, site selection, and operational workflows to move trials forward faster. Download the white paper to learn how agentic AI-driven approaches are reshaping clinical development. Download now: https://hubs.ly/Q04gwhry0 #ClinicalTrials #LifeSciences #AI #AgenticAI #RealWorldData #DrugDevelopment #HealthcareInnovation #ConcertAI

ISPOR 2026 is right around the corner, and ConcertAI is looking forward to connecting in Philadelphia, May 17–20. Learn how our longitudinal, multimodal oncology data platform is helping life sciences teams generate deeper real-world evidence and actionable insights across the patient journey. There’s still time to book a meeting with our team: https://hubs.ly/Q04gwBp_0 #HEOR #RealWorldEvidence #Oncology #PrecisionMedicine #LifeSciences #ConcertAI

We’re excited to share that ConcertAI, in collaboration with Guardant Health, will be presenting " Clinical and Molecular Predictors of Response to Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer" at #AUA2026 on Sunday, May 17 at 3:46 PM. This study evaluated baseline clinical and genomic predictors of response to Lu-177-PSMA-617 in patients with mCRPC using Translational360. Results demonstrated that increasing baseline molecular complexity and specific genomic alterations, were associated with reduced PSA response and poorer survival outcomes following PSMA-targeted RLT. Additionally, this work highlights the value of integrated multimodal real-world data and liquid biopsy to better understand heterogeneity in response to PSMA-targeted RLT in routine clinical practice. Findings support the potential role of genomic profiling and composite molecular risk stratification to inform patient selection, treatment sequencing, and future biomarker-driven combination strategies as PSMA-RLT moves earlier in prostate cancer treatment paradigm. Learn more: https://hubs.ly/Q04gB1tt0 ConcertAI authors: Ruth Pe Benito, Mohammed Sahil KM, Brandon Nathasingh, Sowmya Jairam, Ph.D., Sheenu Chandwani #ProstateCancer #PrecisionOncology #mCRPC #ConcertAI #GuardantHealth

Precision oncology decisions require more than isolated molecular snapshots. Translational360™ connects multi-modal biology with longitudinal clinical context to help biopharma teams generate decision-ready evidence faster. See how ConcertAI is helping accelerate biomarker discovery, patient stratification, and translational research with integrated real-world data and AI. Read the blog: https://lnkd.in/gKem2rjD #PrecisionOncology #RealWorldEvidence #TranslationalResearch #Biopharma #OncologyInnovation #AIinHealthcare